An overview on drug resistant tuberculosis in India by Paramasivan, C N
Review Article Ind. J. Tub., 1998, 45, 73
AN OVERVIEW ON DRUG RESISTANT TUBERCULOSIS IN INDIA
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Introduction
Tuberculosis remains one of the major public
health problems in India. It has been estimated that
about 30% of the world’s tuberculosis patients are
residing in India1. Since the control measures for
tuberculosis such as BCG vaccination and
chemoprophylaxis seem to be unsatisfactory,
treatment with anti-tuberculosis drugs becomes
inevitable. In recent years, the treatment of
tuberculosis has been threatened by the increasing
number of patients with drug resistant tuberculosis.
Although the phenomenon of drug resistance to
Mycobacterium tuberculosis was observed even in
the early days of streptomycin usage, the current
threat is due to the emergence of strains resistant to
the potent bactericidal anti-tuberculosis drugs such
as isoniazid and rifampicin which are used in the
tuberculosis control programmes.
The outcome of treatment of patients harbouring
multiple drug resistant M. tuberculosis has been
poor with a high mortality rate. Their chance of
being cured is very low and they require significant
expenditure of health care resources. They remain
infectious for a prolonged period and may,
therefore, be more likely to infect others. The
resurgence of tuberculosis in New York city in the
1980s is said to be complicated by an increase in
drug resistant strains. Moreover, patients with HIV
infection are known to have a high risk of
tuberculosis and the case fatality rate is high among
patients with AIDS who are infected with strains of
drug resistant M. tuberculosis 2. Thus, the major
concerns over drug resistance are a fear of the
spread of drug resistant organisms and the
ineffectiveness of chemotherapy in patients infected
with them.’
Although a decline in the percentage of drug
resistance in tuberculosis was observed in Korea3
and New York city4 in recent years, the prevalence
rate in India continues to be similar to that in
previous years. In many drug resistance surveys
conducted in India, small or non-representative
populations have been sampled and there has been
no clear distinction between primary and acquired
resistance; these surveys, therefore, do not reflect
the true situation in the community. In spite of such
limitations, an attempt has been made to give an
overview of the prevalence of drug resistance over
the years in India.
The level of drug resistance is said to provide an
epidemiological indicator to assess the amount of
resistant bacterial transmission in the community as
well as the success or otherwise of the National
Tuberculosis Control Programme (NTP). Further,
this influences the design of therapeutic regimens
and policy decisions also5. Before we look at the
prevalence data on drug resistance, it is important to
define drug resistance and the factors responsible
for its emergence.
Definitions
In clinical practice, two types of drug resistance
are recognised, namely, primary and acquired.
Some investigators categorize drug resistant
tuberculosis into primary, acquired, initial, and
transitional resistance6,7. Primary resistance is
defined as the presence of drug resistance in a
tuberculosis patient who has never received prior
treatment with anti-tuberculosis drugs. It is caused
by infection with organisms from another patient
excreting drug resistant organisms. Primary drug
resistance is said to be an indicator of tuberculosis
control efforts in the past. Acquired resistance is
defined as resistance that arises during or after a
course of treatment, usually as a result of non-
adherence to the recommended drug regimen or a
faulty prescription. A high level of this type of
resistance is known to be a mark of a poorly
functioning tuberculosis control programme. The
term initial resistance is preferred by some
investigators to refer to patients presenting with
resistant organisms prior to the commencement of
therapy, since there is a likelihood of a mixture of
true primary drug resistance with acquired drug
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resistance because of patient’s ignorance about
drugs prescibed earlier or deliberate concealing of
information regarding prior treatment. Transitional
resistance is found during treatment where
occasionally a few colonies of resistant cultures are
obtained just before sputum conversion. These
organisms do not multiply, nor does their presence
influence treatment response.
Further,  a  drug resistant  isolate can be
categorised as single or multiple drug resistant.
Multiple drug resistance (MDR) is defined as
resistance to isoniazid (H) and rifampicin (R), with
or without resistance to other drugs.
In contrast to drug resistance in many other
bacterial pathogens, plasmids and transposons are
not involved in M. tuberculosis but unlinked
chromosomal mutation is found to be responsible8.
Inadequate treatment exerts a selective pressure for
the emergence of resistant clones which occurs
when a single drug is used alone while there is a
large viable bacterial population in the lesion.
Factors contributing to the emergence of drug
resistance
There are several explanations given for the
emergence of drug resistance.
* Deficient or deteriorating tuberculosis control
programmes r e s u l t i n g  i n inadequate
administration of effective chemotherapy, poor
case holding, poor quality of drugs and
inadequate drug supply.
* Inadequate training of health care workers
regarding epidemiology, treatment and control
of tuberculosis.
* Improper prescription of treatment regimens
Table 1. Global anti-tuberculosis drug resistance
situation10
Drugs
Isoniazid
Streptomycin
Rifampicin
Ethambutol
M D R
Drug Resistance
Primary Acquired Primary
(%) (%) and Secondary
0 – 16.9 0 – 53.7                  –
0.1 – 23.5 0 – 19.4 –
0 – 3.0 0 – 14.5               –
0 – 4.2 0 – 13.7                –
0 – 10.8 0 – 48.0 0.5-14.3
* Non-adherence of patient to prescribed drug
therapy
* Increase in the number of tuberculosis patients
w i t h  e a s y access to anti-tuberculosis
medication
* The epidemic of HIV infection
* Laboratory delays in identification and
susceptibility testing of M. tuberculosis isolates
etc.,6,9
Drug resistant tuberculosis is mainly an
iatrogenic disease arising under the selective
pressure of inadequate therapy9.
Global prevalence of drug resistant tuberculosis
The prevalence of drug resistant tuberculosis
varies considerably throughout the world. The
reasons for this variation in different surveys are the
degree of selection of patients studied, the degree of
misuse of drugs and the quality of enquiry
regarding previous treatment5. The major limitation
for the adequate assessment of drug resistance is the
inadequate culture and drug susceptibility facilities
in many parts of the world. Therefore, the true
magnitude of global drug resistant tuberculosis is
not known.
The overall percentages of resistance to different
anti-tuberculosis drugs obtained from different
surveys done throughout the world arc shown in
Table I. The available information shows that the
levels of primary resistance to isoniazid as single
agent ranged from 0-16%. High rates of primary
resistance to isoniazid have been reported from
Kenya, India and Haiti, while it is reported to be
low in South Eastern England, Melbourne and
Argentina. The rates of primary resistance to
streptomycin ranges from 0.1-23.5%. High rates of
resistance to streptomycin were reported in Zaire,
Pakistan and Brazil and low levels of resistance
were reported from China, Ethiopia and Bosnia-
Herzegovina. Primary resistance to rifampicin as
single agent was unusual with a rate ranging from
0-3% and the rate of resistance to ethambutol were
similarly low, ranging from 0-4.2%10.
There are fewer surveys of acquired drug
resistance and the rates of acquired resistance are
usually higher than those of primary resistance. The
rates of acquired resistance to isoniazid ranged from
4 to 53.7%, to streptomycin from 0 to 14.5% and to
ethambutol from 0 to 13.7%.
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Resistance to multiple drugs also varied by
geographical region and was more common in
patients with acquired resistance. The rate of MDR-
T was very low in most of the surveys ranging from
0-10.8% in the case of primary resistance and from
0-48% for acquired resistance.  Mult i-drug
resistance was reported to range from 0.5-14.3% in
surveys where there was no distinction between
primary and acquired resistance. Although high
rates of acquired MDR were reported from Nepal
and New York11, in most regions of the world, the
rates of MDR tuberculosis were very low10. In
general, resistance to isoniazid and streptomycin
was found to be more common than to rifampicin
and ethambutol.
Prevalence of drug resistance in India
Drug resistant tuberculosis has frequently been
encountered in India and its presence has been
known from the time anti-tuberculosis drugs were
introduced for the treatment of tuberculosis. The
lack of comprehensive reports on this subject is
mainly due to limited facilities for culture and
susceptibility tests. Much of the drug resistance is
presumed clinically, when patients do not improve
or the symptoms return after initial relief where
sputum remains positive for acid fast bacilli9.
Primary drug resistance
Though primary resistance is found to be low in
developed countries, it is common in India and
varies widely from area to area. The data on
primary drug resistance estimated by different
investigators over the past thirty years are listed in
Table 2.
In the 1960s ICMR conducted two nationwide
surveys at nine urban chest clinics in India12,13. The
results of the first survey showed a resistance level
of 8.2% to isoniazid alone, 5.8% to streptomycin
alone and 6.5% to both the drugs. The primary
resistance levels seen respectively in these two
surveys were 14.7% and 15.5% to isoniazid and
12.5% and 13.8% to streptomycin.
A decade later, a study was conducted to assess
the prevalence of primary drug resistance in
G o v e r n m e n t  C h e s t  I n s t i t u t e  a n d ,  C h e s t
(Tuberculosis) Clinic of Government Stanley
Hospital, Madras .14 The result of the study was
almost similar to the earlier ICMR surveys and the
authors stated that the prevalence of primary drug
resistance had not risen during the span of ten years.
During the 80s, among live reports on primary
drug resistance, though the levels of primary drug
resistance to isoniazid and streptomycin were
similar to the earlier studies, rifampicin resistance
started appearing in North Arcot, Pondicherry,
Bangalore, and Jaipur but not in Gujarat15,16,17,18,19
The reason for the emergence of rifampicin
resistance during this period may be the
introduction of short course chemotherapy- (SCC)
regimens containing rifampicin.
Further, a higher level of primary drug resistance
to isoniazid was observed in the rural population in
Kolar compared to the urban patients, contradicting
a Korean study where a much higher level of initial
resistance was seen among urban patients giving the
reason of easy access to the anti-tuberculosis
drugs3. There was also an increase in the proportion
of primary drug resistance to rifampicin (4.4%)
encountered in this rural population.
In the early 1990s, a retrospective study done at
New Delhi20 showed a high level of primary drug
resistance to isoniazid (18.5%) and a low level of
rifampicin resistance.
Overall, the prevalence rate of primary drug
resistance to isoniazid as single agent ranges from
6.0-13.0% except among the rural population in
Kolar, Karnataka with a high rate of 26.7%, to
streptomycin as single agent from 1.0-5.8% and to
rifampicin from 0-1.9%. It is also seen from these
studies that ethambutol susceptibility was not
performed in many of the surveys.
For a correct evalution of primary drug
resistance, standardised methodology should have
been used taking care of the following namely,
elicting patient history, adequate sample size,
uniform laboratory methods, external and internal
quality control, reliable drugs for setting up drug
susceptibility, media. standard chemicals in the
preparation of media etc. The outcome of Indian
reports may have limitations on the above points.
TRC studies on prevalence of primary drug
resistance
Data from Tuberculosis Research Centre (TRC),
Chennai on primary drug resistance are available
over the past 4 decades and are shown in Figure 1.
Data from 16 different chemotherapy studies from
1956 to 1995 show that there was a gradual increase
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Fig.  1.  Prevalence of primary drug resistance : TRC
studies - 1956 to 1995
in the prevalence of primary drug resistance to anti-
tuberculosis drugs. For isoniazid and streptomycin,
the resistance rates were similar and ranged from 3-
13% with the highest level of 14% during 1990s for
isoniazid. Initial resistance to rifampicin started
appearing in 1990s and was 1.2%. Double drug
resistance (SH) was also noted to a lesser extent
and ranged from 0-7%. Resistance to SHR was
observed to be less than 1% in 1990-95.
Acquired resistance
The rates of acquired resistance are invariably
higher than the rates of primary resistance, though
data on acquired resistance is limited. Studies on
acquired resistance are summarised in Table 3. The
longitudinal trend of drug resistance noted by
Trivedi and Desai between 1980 and 1986 in
Gujarat showed that in treatment failure or relapsed
patients, resistance to rifampicin increased from
2.8% in 1980 to 37.3% in 1986 and to isoniazid
from 34.5% to 55.8%. From this study it was
presumed that high level of rifampicin resistance
was almost entirely acquired15.
When a study was conducted by ICMR in North
Arcot district to compare the efficacy of SCC with
the conventional (non-SCC) chemotherapy, the
populations were examined during their follow-up
period to confirm the bacterial quiesence and in
turn the efficacy of SCC, it was found that there
was an increase in the frequency of acquired drug
resistance with 67% resistance to isoniazid. 26% to
streptomycin and 12% to rifampicin. In addition,
6% of the strains tested were resistant to both
isoniazid and rifampicin21. A New Delhi study in
the 90s also shows a higher level of acquired
resistance to isoniazid and rifampicin which is
almost similar to that of the Gujarat report20.
The overall rates of acquired resistance to
isoniazid ranged from 34.5-67%. for streptomycin
from 26.0-26.9% and for rifampicin from 2.8-
37.3%
Initial drug resistance
The results of the studies on initial drug resistant
tuberculosis are shown in Table 4. The second
ICMR survey conducted in the 1960s showed a
higher level of drug resistance among those with a
history of previous chemotherapy and it was 7.0%
to isoniazid, 9.1% to streptomycin and 15.8% of
both the drugs13. During the 80s, two surveys were
conducted by ICMR at Raichur district, Karnataka22.
and North Arcot district, Tamil Nadu to estimate the
prevalence of tuberculosis and the results of the
survey showed a higher level of initial drug
resistance in Raichur District compared to that in
North Arcot District.
Data on the prevalence of drug resistance from
Army Hospital, Pune showed a very low level of
initial resistance to isoniazid and the authors have
reasoned that this lower level of drug resistance in
this population could be due to the minimal chance
of indiscriminate exposure of anti-tuberculosis
agents prior to reporting to the hospital23.
Overall, the initial resistance to isoniazid as
single agent ranges  f rom 0 .6 -13 .2%,  to
streptomycin from 2.2-7.0% and to rifampicin from
0-1.7%.
Multi-drug resistance (MDR-TB)
The rate of MDR-TB in India is very low and
ranged from 0-6% (Table 2, 3 and 4). Primary
MDR-TB is found to be < 3.2% and even the level
of acquired MDR-TB is < 6.0% except in Gujarat
where a high level was observed (11.4-18.5%)15.
When compared to the prevalence of MDR-TB in
other parts of the world where upto 18% have been
encountered, lower level has been reported in
Indian studies.
Diagnosis of drug resistance
Since the spectrum of disease caused by drug
resistant and susceptible organisms is similar, only
way of diagnosing drug resistance is by isolating
the infecting strain and assessing its susceptibility
pattern which takes months for the results to be
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available. New rapid culture and susceptibility tests,
namely BACTEC, mycobacterial growth indicator
tube (MGIT) and luciferase reporter assay have
been developed which offer the possibility of early
sensitivity results. In addition, advanced molecular
biological techniques such as polymerase chain
reaction (PCR), DNA finger printing and ligase
reaction are said to be highly specific, sensitive and
rapid and make the results available in clinically
useful time. These molecular methods not only
enable us to identify resistant genes but also help in
tracing dissemination24. Experience in restriction
fragment length polymorphism (RFLP) finger
printing of M. tuberculosis shows that clustering is
more common among patients with multi-drug
resistant isolates than unique isolates26.
Treatment o u t c o m e  o f drug resistant
tuberculosis
The emergence of drug resistant strains is known
to reduce the efficacy of treatment. Strains resistant
to isoniazid and streptomycin (H/S/SH) neither
pose a major problem nor affect the result of
treatment in a big way provided proper regimens
are used26. On the contrary, patients infected with
organisms resistant to rifampicin and isoniazid (R/
HR) have a high rate of treatment failure16,20,26 and
this forms a major threat to tuberculosis control
particularly for countries like India with poor
resources. Patients infected with MDR strains
require longer duration of therapy and may die of
tuberculosis or continue to have active tuberculosis
despite optional therapy2.
Comment
In view of the results so for observed, there is
no clear evidence of an increase in the prevalence
of primary drug resistance in India over the
years. Moreover, relatively high prevalence of
acquired resistance has been reported from
Gujarat, North Arcot district  and New
Delhi l6,22.21. When compared to the global
prevalence of drug resistance, primary drug
resistance is found to be marginally lesser and a
much higher level of acquired resistance is
observed in India. The magnitude of drug resistance
problem, to a large extent, is due to acquired
resistance. The prevalence of MDR-TB also is
found to be at a very low level in most of the
regions of India. Since paediatric cases and
resistance in them are mirror reflection of adult
tuberculosis cases9, the low level of resistance to
isoniazid and streptomycin with 5-10% and 2-
11.4% respectively and with a nil resistance to
rifampicin observed in Indian children27,28,29 really
indicate that there is apparently no alarming
increase in the incidence of init ial  MDR
tuberculosis cases. However, these studies require
to be repeated in different regions and in diverse
settings to reconfirm this belief.
The lesson learnt from the New York study4
where a decline in the prevalence of drug
resistance was observed, is that a strong
tuberculosis programme that can reduce the
incidence of drug resistance in a community
reduces the level of multiple drug resistance.
Particularly, directly observed therapy (DOT)
which is cost effective, efficient for treatment
completion and in turn effective against
emergence of drug resistance11. New drugs for
tuberculosis arc unlikely to come up in the near
future and hence the key success remains in
adequate case finding, prompt and correct
diagnosis and effective treatment of infectious
Table 3. Summary of studies on acquired drug resistance among M. tuberculosis isolates in India
S. Location Year No. of Resistance (%) U/R
No. isolates
H S R SH HR SR SHR
Gujarat15 1980-86 1574 34.5- 26.3 2.8 -
55.8 26.9 37.3
1983-86 1267 -. 11.4- 3.5- 14.5-
18.5 1.2 15.3
2. North Arcot21 1988-89 560 67.0 26.0 12.0 19. 0 6.0 R
3. New Delhi20 1990-91 81 50.7 - 33.7 U
H-Isoniazid, S-Streptomycin, R-Rifampicin, U-Urban, R-Rural
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patients for prevention of drug resistance.
Although longitudinal studies of TRC and many
of the above cited surveys, including studies on
childhood tuberculosis, show that there is no real
threat due to the increase of MDR-TB in India, it
cannot be taken lightly. Every physician and health
care personnel should strictly adhere to the
treatment policies of the government and ensure
completion of treatment which would eventually
result in the reduction in the prevalence of MDR-
TB in the community as was observed elsewhere.
Apart from a strong tuberculosis control
programme, there is also a need for a continuous
and/or periodic survey of drug resistance which
will  provide information on the type of
chemotherapy to be used for the treatment of
patients and also serve as a useful parameter in
the evaluation of current and past chemotherapy
programmes 3. More recently, surveillance systems
have been initiated throughout the world including
India by the World Health Organisation (WHO)
with an emphasis on internal quality control and
external quality assessment to monitor the
prevalence of drug resistant organisms especially
MDR-TB in the community30 which is expected to
provide accurate data on the prevalence of drug
resistance in the community.
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